Study of GS-0201 alone and combined for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called GS-0201, either by itself or with other treatments, for people with advanced solid tumors. The goal is to see if it is safe and helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and able to give permission to join the study.
- You need to have a type of advanced solid tumor that has been confirmed by a biopsy or other test.
- You should be in generally good health, as measured by a standard scale (ECOG 0 or 1).
- You must have at least one tumor that can be measured on scans (like CT or MRI).
- You need to agree to provide a tumor tissue sample before starting treatment, and possibly during treatment as well.
- You cannot be pregnant or breastfeeding, and must use effective birth control if sexually active.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, GS-2121, given alone or with other therapies, for adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
This study is testing an investigational drug called SG1827, either alone or combined with other standard immunotherapy medicines, for advanced solid tumors. The goal is to see if this combination can help shrink or slow the growth of the tumor.
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called GS-1206 for adults with solid tumors that have a specific genetic change. It aims to see if the drug is safe and can shrink or slow the growth of the cancer after other treatments have stopped working.
This trial tests an immunotherapy drug called GLS-012, alone and with another drug (GLS-010), in people with advanced solid cancers that have worsened despite standard treatment. It aims to see how well the treatment works and how safe it is, especially when given in different combinations.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.